Puma Biotechnology (PBYI)
(Delayed Data from NSDQ)
$2.60 USD
+0.04 (1.56%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $2.60 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum A VGM
Brokerage Reports
0 items in cart
Puma Biotechnology, Inc. [PBYI]
Reports for Purchase
Showing records 1 - 20 ( 242 total )
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
2Q24 Results; Nerlynx Sales Within Guidance, Up Sequentially
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Compelling Alisertib Data in Advanced NSCLC Patients With TP53 Wild-Type
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Biomarker Findings From Phase 2 Study of Alisertib May Help Determine Which Patients Could Benefit From Treatment
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Patent Infringement Win Could Reap Financial Benefits for Puma
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; Nerlynx Sales Slightly Above Prior Guidance; FY24 Guidance Unchanged; Alisertib Posters at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department